Clinical Trial Update: Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating isatuximab added to RVd induction and lenalidomide maintenance for newly diagnosed multiple myeloma; currently active but not recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Revlimid (lenalidomide) (lenalidomide)
• Sarclisa (isatuximab) (isatuximab)
• Velcade (bortezomib) (bortezomib)

Snippet

Sponsor: University of Heidelberg Medical Center | Conditions: Multiple Myeloma | Phase 3 | Status: ACTIVE_NOT_RECRUITING